GAM Holding AG Sells 469 Shares of IQVIA Holdings Inc. (NYSE:IQV)

GAM Holding AG reduced its position in IQVIA Holdings Inc. (NYSE:IQV) by 7.4% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 5,890 shares of the medical research company’s stock after selling 469 shares during the quarter. GAM Holding AG’s holdings in IQVIA were worth $1,157,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Smith Group Asset Management LLC bought a new position in shares of IQVIA in the fourth quarter valued at approximately $1,616,000. Simplify Asset Management Inc. lifted its position in IQVIA by 67.8% during the third quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company’s stock valued at $2,284,000 after purchasing an additional 3,894 shares during the last quarter. Nordea Investment Management AB lifted its position in IQVIA by 47.4% during the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock valued at $277,908,000 after purchasing an additional 452,029 shares during the last quarter. Fifth Third Bancorp lifted its position in IQVIA by 13.0% during the fourth quarter. Fifth Third Bancorp now owns 13,179 shares of the medical research company’s stock valued at $2,590,000 after purchasing an additional 1,521 shares during the last quarter. Finally, Graphene Investments SAS lifted its position in IQVIA by 22.0% during the fourth quarter. Graphene Investments SAS now owns 15,000 shares of the medical research company’s stock valued at $2,948,000 after purchasing an additional 2,700 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors.

Insider Buying and Selling at IQVIA

In related news, Director John G. Danhakl acquired 1,275 shares of IQVIA stock in a transaction on Tuesday, December 3rd. The shares were acquired at an average cost of $200.58 per share, with a total value of $255,739.50. Following the transaction, the director now owns 1,275 shares in the company, valued at $255,739.50. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 1.60% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. Leerink Partners reiterated an “outperform” rating and set a $248.00 target price (down from $260.00) on shares of IQVIA in a research report on Tuesday, November 19th. Stephens initiated coverage on shares of IQVIA in a research report on Friday, December 20th. They set an “overweight” rating and a $250.00 target price for the company. JPMorgan Chase & Co. lowered their price objective on shares of IQVIA from $240.00 to $232.00 and set an “overweight” rating for the company in a report on Tuesday. Robert W. Baird lowered their price objective on shares of IQVIA from $212.00 to $210.00 and set a “neutral” rating for the company in a report on Tuesday, January 21st. Finally, The Goldman Sachs Group lowered their price objective on shares of IQVIA from $280.00 to $250.00 and set a “buy” rating for the company in a report on Friday, November 1st. Four equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, IQVIA has an average rating of “Moderate Buy” and a consensus price target of $251.22.

IQVIA Stock Down 0.1 %

Shares of IQVIA stock opened at $193.27 on Wednesday. The company has a current ratio of 0.84, a quick ratio of 0.81 and a debt-to-equity ratio of 2.12. The company’s fifty day simple moving average is $200.15 and its two-hundred day simple moving average is $217.43. The company has a market cap of $35.08 billion, a P/E ratio of 25.77, a PEG ratio of 2.25 and a beta of 1.48. IQVIA Holdings Inc. has a 12-month low of $187.62 and a 12-month high of $261.73.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Research analysts anticipate that IQVIA Holdings Inc. will post 10.81 EPS for the current year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.